Eloxx Pharmaceuticals Statistics
Total Valuation
ELOX has a market cap or net worth of $42.99 million. The enterprise value is -$1.44 million.
Important Dates
The last earnings date was Monday, November 16, 2026, before market open.
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ELOX has 4.04 million shares outstanding. The number of shares has increased by 1,790.77% in one year.
| Current Share Class | 4.04M |
| Shares Outstanding | 4.04M |
| Shares Change (YoY) | +1,790.77% |
| Shares Change (QoQ) | +67.99% |
| Owned by Insiders (%) | 3.84% |
| Owned by Institutions (%) | 19.08% |
| Float | 947,750 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.29.
| Current Ratio | 3.39 |
| Quick Ratio | 3.27 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.73 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.19% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -42.73% |
| Weighted Average Cost of Capital (WACC) | -734,811.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.58M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +106,499,900.00% in the last 52 weeks. The beta is -169,223.47, so ELOX's price volatility has been lower than the market average.
| Beta (5Y) | -169,223.47 |
| 52-Week Price Change | +106,499,900.00% |
| 50-Day Moving Average | 14.12 |
| 200-Day Moving Average | 8.79 |
| Relative Strength Index (RSI) | 32.19 |
| Average Volume (20 Days) | 24,461 |
Short Selling Information
The latest short interest is 52,603, so 1.30% of the outstanding shares have been sold short.
| Short Interest | 52,603 |
| Short Previous Month | 41,345 |
| Short % of Shares Out | 1.30% |
| Short % of Float | 5.55% |
| Short Ratio (days to cover) | 2.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.55M |
| Pretax Income | -15.84M |
| Net Income | -15.84M |
| EBITDA | n/a |
| EBIT | -17.55M |
| Earnings Per Share (EPS) | -$2.46 |
Full Income Statement Balance Sheet
The company has $56.26 million in cash and $11.84 million in debt, with a net cash position of $44.43 million or $11.01 per share.
| Cash & Cash Equivalents | 56.26M |
| Total Debt | 11.84M |
| Net Cash | 44.43M |
| Net Cash Per Share | $11.01 |
| Equity (Book Value) | 41.07M |
| Book Value Per Share | 10.05 |
| Working Capital | 41.07M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -18.58M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -300,000 |
| Free Cash Flow | -18.58M |
| FCF Per Share | -$4.60 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,790.77% |
| Shareholder Yield | -1,790.77% |
| Earnings Yield | -23.05% |
| FCF Yield | -41.85% |
Analyst Forecast
The average price target for ELOX is $37.50, which is 252.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.50 |
| Price Target Difference | 252.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on June 1, 2026. It was a reverse split with a ratio of 1:11.
| Last Split Date | Jun 1, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:11 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |